{"id":"NCT01863771","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.","officialTitle":"A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-15","primaryCompletion":"2016-01-29","completion":"2016-01-29","firstPosted":"2013-05-29","resultsPosted":"2017-02-17","lastUpdate":"2017-04-05"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Colitis, Ulcerative"],"interventions":[{"type":"DRUG","name":"Golimumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Golimumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate safety and effectiveness of golimumab in Japanese participants with moderately to severely active ulcerative colitis.","primaryOutcome":{"measure":"Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score","timeFrame":"Up to Week 54","effectByArm":[{"arm":"Placebo","deltaMin":6,"sd":null},{"arm":"Golimumab","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":38,"countries":["Japan"]},"refs":{"pmids":["28324167"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":144},"commonTop":["Nasopharyngitis","Colitis Ulcerative","Injection Site Erythema","Influenza","Headache"]}}